In the first known study to examine the prevalence and treatment of psoriasis in older Americans, experts have found that black patients receiving Medicare are less likely to receive biologic therapies -medications derived from human or animal cells or tissues -- for the treatment of moderate to severe psoriasis than white patients.
Psoriasis and psoriatic arthritis symptoms were significantly lessened in patients who underwent bariatric -- or weight loss -- surgery, according to researchers. According to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial.
A phase II clinical trial shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition. Psoriasis is an immune-mediated disease that causes itchy, dry and red skin. It also increases a patient's risk for depression, heart disease and diabetes, among other conditions. The disease affects nearly 3 percent of the world's population.
The results of a large population study showed an increased risk of developing Psoriatic Arthritis among psoriasis patients exposed to physical trauma, particularly when the trauma involved bone and/or joints.
Biological treatment of psoriasis shows a good efficacy in clinical trials. Since most analyses have focused on short-term outcomes of single biological agents, little has been known about long-term...